Stock Yards Bank & Trust Co. boosted its stake in shares of Celgene Corporation (NASDAQ:CELG) by 2.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 119,387 shares of the biopharmaceutical company’s stock after acquiring an additional 2,752 shares during the period. Celgene Corporation comprises about 1.9% of Stock Yards Bank & Trust Co.’s holdings, making the stock its 14th biggest holding. Stock Yards Bank & Trust Co.’s holdings in Celgene Corporation were worth $15,505,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Sowell Financial Services LLC raised its position in Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 13 shares during the period. South Texas Money Management Ltd. raised its position in Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 15 shares during the period. Flagship Harbor Advisors LLC raised its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares during the period. Keel Point LLC raised its position in Celgene Corporation by 0.9% during the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock worth $386,000 after acquiring an additional 28 shares during the period. Finally, Steinberg Global Asset Management raised its position in Celgene Corporation by 0.6% during the first quarter. Steinberg Global Asset Management now owns 6,594 shares of the biopharmaceutical company’s stock worth $820,000 after acquiring an additional 39 shares during the period. Institutional investors own 79.43% of the company’s stock.

In other news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the sale, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders have sold a total of 267,476 shares of company stock valued at $35,812,841 in the last quarter. Company insiders own 0.95% of the company’s stock.

A number of equities analysts have weighed in on the stock. Mizuho upped their price objective on shares of Celgene Corporation from $134.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank Of Canada assumed coverage on shares of Celgene Corporation in a research report on Thursday. They set a “top pick” rating and a $176.00 price objective for the company. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a research report on Wednesday. Cowen and Company restated a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Tuesday. Finally, Vetr cut shares of Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 price objective for the company. in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and a consensus price target of $149.34.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/celgene-corporation-celg-shares-bought-by-stock-yards-bank-trust-co.html.

Shares of Celgene Corporation (NASDAQ CELG) traded up 1.02% during mid-day trading on Friday, hitting $142.04. 5,983,997 shares of the stock traded hands. The company has a market cap of $111.12 billion, a P/E ratio of 43.99 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $142.69. The stock has a 50 day moving average price of $134.97 and a 200-day moving average price of $127.46.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the previous year, the business earned $1.44 EPS. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, analysts forecast that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.